Advances in the pathogenesis of autoimmune hepatitis and new targets for clinical intervention
10.3969/j.issn.1001-5256.2022.04.002
- VernacularTitle:自身免疫性肝炎发病机制进展与临床干预新靶点
- Author:
Mingli HU
1
;
Qixia WANG
1
;
Xiong MA
1
Author Information
1. Shanghai Institute of Digestive Disease, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis, Autoimmune;
Pathologic Processes;
Therapeutics;
Targets
- From:
Journal of Clinical Hepatology
2022;38(4):743-747
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune hepatitis (AIH) is an immune-mediated liver disease with hepatocytes as the main target cells. It is characterized by the high immunoglobulin G level and the presence of autoantibodies, and histological observation shows interface hepatitis at the portal area caused by a large amount of lymphoplasmacytic infiltration. The pathogenesis of AIH has not been fully elucidated. At present, glucocorticoid combined with azathioprine is mainly used as non-specific immunosuppressive therapy, and most patients tend to have good response; however, rebound or relapse is often observed during dose reduction or after drug withdrawal, so most patients need long-term maintenance therapy. This article briefly reviews the advances in the pathogenesis of AIH and the potential new targets for clinical intervention, in order to provide a reference for clinical translational research.
